Response to crizotinib in a lung adenocarcinoma patient harboring a novel - fusion variant.

fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel - fusion variant, which was different from the two common - fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal.